More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma
Thursday, November 24, 2011 - 18:30
in Health & Medicine
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years later, compared with patients given standard chemotherapy treatment plus rituximab, according to an article published Online First in the Lancet.